SONOMA PHARMACEUTICALS INC

SONOMA PHARMACEUTICALS INC

Aktie · US83558L2043 · SNOA · A2PMPH (XNCM)
Übersicht
AI-gestützte Analyse
Fundamental-Analyse
Was die Zahlen wirklich bedeuten – bevor der Markt es weiß.
Jetzt analysieren
News Sentiment
Kaufchance oder Alarmsignal? Was die aktuellen Nachrichten wirklich bedeuten.
Jetzt analysieren
Kaufen / Halten / Verkaufen
Kaufen, Halten oder Verkaufen? Das AI-Urteil auf einen Blick.
Jetzt analysieren
Risiko-Bewertung
Risiken erkennen, bevor sie zum Problem werden.
Jetzt analysieren
Fair Value
Zu teuer, fair bewertet oder ein Schnäppchen?
Jetzt analysieren
Neuste KI Analysen zu SONOMA PHARMACEUTICALS INC
Analyst Grade Summary
gauge-img
Kaufen
Starker Kauf
Kaufen
Halten
Verkaufen
Starker Verkauf
0
1
1
0
0
Kein Kurs
29.04.2026 16:22
Aktuelle Kurse von SONOMA PHARMACEUTICALS INC
BörseTickerWährungLetzter UmsatzKursTagesveränderung
IEXG: IEX
IEX
SNOA
USD
29.04.2026 16:22
1,07 USD
0,02 USD
+2,40 %
XNAS: NASDAQ
NASDAQ
SNOA
USD
29.04.2026 16:07
1,08 USD
0,04 USD
+3,85 %
Free Float & Liquidität
Free Float 98,79 %
Shares Float 1,72 M
Ausstehende Aktien 1,74 M
Firmenprofil zu SONOMA PHARMACEUTICALS INC Aktie
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Unternehmensdaten

Name SONOMA PHARMACEUTICALS INC
Firma Sonoma Pharmaceuticals, Inc.
Symbol SNOA
Website https://www.sonomapharma.com
Heimatbörse XNCM NASDAQ CAPITAL MARKET
WKN A2PMPH
ISIN US83558L2043
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Amy M. Trombly
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,0 T
Adresse 645 Molly Lane, 30189 Woodstock
IPO Datum 2007-01-25

Aktien-Splits

Datum Split
30.08.2024 1:20
20.06.2019 1:9
27.06.2016 1:5
01.04.2013 1:7

Kennungswechsel

Datum Von Zu
19.12.2016 OCLS SNOA

Ticker Symbole

Name Symbol
Frankfurt O8Z3.F
NASDAQ SNOA
Weitere Aktien
Investoren, die SONOMA PHARMACEUTICALS INC halten, haben auch folgende Aktien im Depot:
ROYAL BANK OF CANADA 0.875% CVD BDS 17/06/22 RULE144A
ROYAL BANK OF CANADA 0.875% CVD BDS 17/06/22 RULE144A Anleihe
WORLD BK 24/27 MTN
WORLD BK 24/27 MTN Anleihe